New Treatments for Cancer Based on the Immune System
Dr. Ronald Levy is Professor and Chief of the Division of Oncology at the Stanford School of Medicine. He has been a pioneer in the development of monoclonal antibodies for the treatment of cancer and is a world-renowned expert in cancer research and treatment with targeted therapies. Dr. Levy specializes in lymphoma, including non-Hodgkins lymphoma, Burkitt's lymphoma and Hodgkin's disease. His research investigates how the immune system can be harnessed to fight lymphoma; his work has led to the concept that antibodies can be used as personalized anticancer drugs and to the development of an antibody-based drug, Rituxan, that is widely used to treat lymphoma. Dr. Levy's pioneering research has been recognized with multiple honors and awards, including the American Cancer Society's Medal of Honor and the Leukemia and Lymphoma Society's di Villiers International Achievement Award.
This program is presented by Beth Am's Health Initiative, which helps our congregation fulfill the Jewish mandate to care for our physical and emotional health.